成都康弘药业集团股份有限公司 关于子公司收到药物临床试验补充申请批准通知书的公告

Group 1 - The company, Chengdu Kanghong Pharmaceutical Group Co., Ltd., announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received a clinical trial supplement application approval notice from the National Medical Products Administration for the drug Kangbaisipu Eye Injection [1][2] - Kangbaisipu Eye Injection is a Class 1 innovative biological drug independently developed by the company, which effectively binds to VEGF in blood and tissues, blocking the signaling pathways that promote neovascularization [2] - The approval allows for the exploration of high-dose Kangbaisipu Eye Injection in clinical applications, which is expected to improve patient compliance and reduce medical burdens [2]